The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Madeleine Duvic

Department of Dermatology

University of Texas

MD Anderson Cancer Center

Houston

USA

[email]@mdanderson.org

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, USA. 2000 - 2011
  • The University of Texas MD Anderson Cancer Center, Division of Internal Medicine, Department of Dermatology, 1515 Holcombe Blvd, USA. 2008

References

  1. CD30+ Neoplasms of the Skin. Duvic, M. Curr. Hematol. Malig. Rep (2011) [Pubmed]
  2. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome. Duvic, M., Donato, M., Dabaja, B., Richmond, H., Singh, L., Wei, W., Acholonu, S., Khouri, I., Champlin, R., Hosing, C. J. Clin. Oncol. (2010) [Pubmed]
  3. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma. Duvic, M., Olsen, E.A., Breneman, D., Pacheco, T.R., Parker, S., Vonderheid, E.C., Abuav, R., Ricker, J.L., Rizvi, S., Chen, C., Boileau, K., Gunchenko, A., Sanz-Rodriguez, C., Geskin, L.J. Clin. Lymphoma. Myeloma (2009) [Pubmed]
  4. Optimizing denileukin diftitox (Ontak) therapy. Duvic, M., Talpur, R. Future. Oncol (2008) [Pubmed]
  5. Vorinostat in cutaneous T-cell lymphoma. Duvic, M., Vu, J. Drugs. Today (2007) [Pubmed]
  6. Mycosis fungoides: pathophysiology and emerging therapies. Duvic, M., Foss, F.M. Semin. Oncol. (2007) [Pubmed]
  7. Systemic monotherapy vs combination therapy for CTCL: rationale and future strategies. Duvic, M. Oncology (Williston Park, N.Y.) (2007) [Pubmed]
  8. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Duvic, M., Vu, J. Expert. Opin. Investig. Drugs (2007) [Pubmed]
  9. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J.H., Reilly, J.F., Ricker, J.L., Richon, V.M., Frankel, S.R. Blood (2007) [Pubmed]
  10. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Duvic, M., Talpur, R., Wen, S., Kurzrock, R., David, C.L., Apisarnthanarax, N. Clinical. Lymphoma. &. Myeloma (2006) [Pubmed]
  11. Photopheresis versus transimmunization?. Duvic, M. Leuk. Lymphoma (2006) [Pubmed]
  12. A phase II open-label study of recombinant human interleukin-12 in patients with stage IA, IB, or IIA mycosis fungoides. Duvic, M., Sherman, M.L., Wood, G.S., Kuzel, T.M., Olsen, E., Foss, F., Laliberté, R.J., Ryan, J.L., Zonno, K., Rook, A.H. J. Am. Acad. Dermatol. (2006) [Pubmed]
  13. Cutaneous T-cell lymphoma. Duvic, M., Edelson, R. J. Am. Acad. Dermatol. (2004) [Pubmed]
  14. Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma. Duvic, M., Chiao, N., Talpur, R. J. Cutan. Med. Surg (2003) [Pubmed]
  15. Alopecia areata registry: an overview. Duvic, M., Norris, D., Christiano, A., Hordinsky, M., Price, V. J. Investig. Dermatol. Symp. Proc. (2003) [Pubmed]
  16. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. Duvic, M., Ni, X., Talpur, R., Herne, K., Schulz, C., Sui, D., Ward, S., Joseph, A., Hazarika, P. J. Invest. Dermatol. (2003) [Pubmed]
  17. Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK). Duvic, M., Kuzel, T.M., Olsen, E.A., Martin, A.G., Foss, F.M., Kim, Y.H., Heald, P.W., Bacha, P., Nichols, J., Liepa, A. Clin. Lymphoma (2002) [Pubmed]
  18. Emerging new therapies for cutaneous T-cell lymphoma. Duvic, M., Cather, J.C. Dermatol. Clin (2000) [Pubmed]
  19. Expression of a retinoid-inducible tumor suppressor, Tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. Duvic, M., Helekar, B., Schulz, C., Cho, M., DiSepio, D., Hager, C., DiMao, D., Hazarika, P., Jackson, B., Breuer-McHam, J., Young, J., Clayman, G., Lippman, S.M., Chandraratna, R.A., Robinson, N.A., Deucher, A., Eckert, R.L., Nagpal, S. Clin. Cancer Res. (2000) [Pubmed]
  20. Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials. Duvic, M., Friedman-Kien, A.E., Looney, D.J., Miles, S.A., Myskowski, P.L., Scadden, D.T., Von Roenn, J., Galpin, J.E., Groopman, J., Loewen, G., Stevens, V., Truglia, J.A., Yocum, R.C. Arch. Dermatol (2000) [Pubmed]
  21. Enterococcal eschars in cutaneous T-cell lymphoma tumors: a distinct clinical entity. Duvic, M., Feasel, A.M., Schwartz, C.A., Cather, J.C. Clin. Lymphoma (2000) [Pubmed]
  22. Treatment of cutaneous T-cell lymphoma from a dermatologist's perspective. Duvic, M. Clin. Lymphoma (2000) [Pubmed]
  23. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms. Duvic, M. Clin. Lymphoma (2000) [Pubmed]
 
WikiGenes - Universities